Stay updated on Single Dose GHB16L2 Trivalent Influenza Vaccine Clinical Trial
Sign up to get notified when there's something new on the Single Dose GHB16L2 Trivalent Influenza Vaccine Clinical Trial page.

Latest updates to the Single Dose GHB16L2 Trivalent Influenza Vaccine Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about the GHB16L2 influenza vaccine study, such as its purpose, methodology, and inclusion/exclusion criteria. Additionally, the principal investigator's name has been removed, and the revision number has been updated.SummaryDifference25%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check95 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Single Dose GHB16L2 Trivalent Influenza Vaccine Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Single Dose GHB16L2 Trivalent Influenza Vaccine Clinical Trial page.